FDA Opioid Warning Labels Overdose Risk
- STAT's coverage of chronic health issues is supported by a grant from Bloomberg Philanthropies.
# FDA Revises Opioid Labels, Removing “Extended Treatment Period” to Combat Misinformation
The U.S. Food and Drug Administration (FDA) has announced a significant revision to the labeling of opioid medications, a move aimed at curbing the ongoing opioid crisis by eliminating the phrase “extended treatment period.” this change seeks to prevent the misperception that long-term data supports the prolonged use of these powerful painkillers, a concern amplified by the nation’s struggle with opioid addiction.
### The Opioid Crisis: A Persistent Public Health Challenge
the extent to which the FDA’s move will have a significant impact on public health is unclear. Opioids and the overdose crisis are seared into many Americans’ consciousness thanks to countless books and TV shows and continued media attention. Many have been directly affected, or have had family or friends who have been.
Annual opioid prescriptions in the U.S. are also down sharply from their peak over a decade ago, as American medical providers respond to the opioid epidemic and increased scrutiny of their prescribing practices.Deaths involving prescription opioids but not involving illicit substances, like heroin or fentanyl, have declined consistently as peaking in 2011, according to the National Institute on drug Abuse.
### Expert Insights and the Rationale Behind the Change
In a recent interview, Dr. Marty Makary,a prominent gastrointestinal surgeon and vocal critic of past opioid prescribing practices,foreshadowed the move. he referenced his own decision-making as a prescriber and cited OxyContin, which was approved without data supporting its long-term use.
“I feel terrible about the opioid epidemic: I personally prescribed opioids with misinformation,” Makary said in a July 11 interview with Bloomberg.”We’re going to look at the label for OxyContin and that class of medications and ask,’How can we ensure that it’s accurate and consistent with the science?'”
Accordingly,the FDA is removing the phrase “extended treatment period” from opioid labels,in an effort to avoid leaving the false impression that data exist supporting the medications’ use over the long term. This proactive measure aims to align prescribing data with current scientific understanding and mitigate the risk of continued over-reliance on these drugs.
### Medical Community Applauds FDA’s Proactive stance
in a statement,the American Medical Association (AMA),which has previously opposed new requirements that physicians receiving training about opioid use disorder,applauded the FDA’s move. The AMA stated that the change emphasizes “shared decision-making” between patients and doctors,fostering a more informed approach to pain management.
“The AMA agrees that decisions whether to begin opioid therapy must be made on whether the benefits outweigh the known risks,” said Bobby Mukkamala,the AMA’s president. “We agree that – if opioid therapy is indicated -physicians should start low and go slow. We further agree with the FDA that rapid escalations and rapid discontinuation should not occur to avoid patient harm.”
This collaborative approach between regulatory bodies and medical associations underscores a commitment to patient safety and a more responsible strategy for addressing chronic pain, ultimately aiming to reduce the devastating impact of the opioid epidemic.
STAT’s coverage of chronic health issues is supported by a grant from Bloomberg Philanthropies. Our financial supporters are not involved in any decisions about our journalism.